{
    "hands_on_practices": [
        {
            "introduction": "The decision to initiate immunotherapy is increasingly guided by predictive biomarkers. Among the most important is Tumor Mutational Burden (TMB), which serves as a surrogate for the neoantigen landscape of a tumor. This practice provides a hands-on opportunity to calculate TMB from genomic sequencing data, a fundamental skill for interpreting molecular reports and determining patient eligibility for immune checkpoint blockade. ",
            "id": "4631856",
            "problem": "A surgical oncology team is evaluating a patient with resectable cutaneous melanoma for perioperative immune checkpoint blockade targeting Programmed Cell Death Protein 1 (PD-1). The tumor specimen underwent whole-exome capture, yielding a captured coding region length of $35$ megabases. Variant calling after standard germline filtering identified $350$ nonsynonymous somatic mutations in the captured region. Based on accepted usage in clinical translational oncology, Tumor Mutational Burden (TMB) is operationally defined as the number of nonsynonymous somatic mutations per megabase of coding sequence interrogated by the assay.\n\nUsing this definition as the fundamental base, compute the TMB for this specimen. Then, determine whether the calculated TMB meets a commonly used immunotherapy consideration threshold of $\\geq 10$ mutations per megabase for potential PD-1 blockade. Express the TMB in mutations per megabase (mut/Mb). Provide an exact value for the TMB; no rounding is required. Your final boxed answer must only be the numerical value of the TMB.",
            "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\nThe givens extracted verbatim from the problem statement are:\n- Captured coding region length: $35$ megabases (Mb).\n- Number of nonsynonymous somatic mutations identified: $350$.\n- Operational definition of Tumor Mutational Burden (TMB): \"the number of nonsynonymous somatic mutations per megabase of coding sequence interrogated by the assay\".\n- Immunotherapy consideration threshold: $\\geq 10$ mutations per megabase (mut/Mb).\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded**: The problem is grounded in the established principles of surgical oncology and cancer genomics. Tumor Mutational Burden (TMB) is a recognized biomarker for predicting response to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapy. The definition provided is the standard operational definition used in clinical practice. The values for exome capture size ($35$ Mb) and the number of mutations ($350$) are realistic for cutaneous melanoma, which is known for its high mutational load due to ultraviolet radiation exposure. The threshold of $10$ mut/Mb is a commonly cited, though simplified, cutoff for classifying tumors as \"TMB-High\". The problem is scientifically and factually sound.\n- **Well-Posed**: The problem is well-posed. It provides a clear, unambiguous definition for TMB and all the necessary data to calculate it. A unique numerical solution exists.\n- **Objective**: The language is objective, technical, and free from subjective or opinion-based claims.\n- **Completeness and Consistency**: The problem is self-contained and free of contradictions. The data provided are sufficient for the required calculation.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically sound, well-posed, objective, and contains all necessary information for a solution. The solution process will proceed.\n\n**Solution**\nThe primary task is to compute the Tumor Mutational Burden (TMB) for the given specimen and evaluate it against a specified clinical threshold.\n\nThe problem explicitly defines TMB as the number of nonsynonymous somatic mutations per megabase of the interrogated coding sequence. Let $N_{mut}$ represent the number of nonsynonymous somatic mutations and $L_{coding}$ represent the length of the captured coding region in megabases (Mb). The formula for TMB is therefore:\n$$ \\text{TMB} = \\frac{N_{mut}}{L_{coding}} $$\n\nThe units of TMB will be mutations per megabase (mut/Mb). From the problem statement, we have the following values:\n- $N_{mut} = 350$\n- $L_{coding} = 35$ Mb\n\nSubstituting these values into the formula:\n$$ \\text{TMB} = \\frac{350}{35} \\text{ mut/Mb} $$\n\nPerforming the division yields the exact value for the TMB:\n$$ \\text{TMB} = 10 \\text{ mut/Mb} $$\n\nThe second part of the task is to determine whether this calculated TMB meets the immunotherapy consideration threshold. The threshold is given as $\\geq 10$ mut/Mb.\n\nWe compare the calculated TMB to the threshold:\nCalculated TMB: $10$ mut/Mb.\nThreshold: $\\geq 10$ mut/Mb.\n\nThe condition to be checked is $10 \\geq 10$. This inequality is true. Therefore, the TMB for this specimen meets the specified threshold for consideration of PD-1 blockade immunotherapy.\n\nThe problem asks for the numerical value of the TMB as the final answer.",
            "answer": "$$\\boxed{10}$$"
        },
        {
            "introduction": "Evaluating treatment response to immunotherapy presents unique challenges, as conventional radiographic criteria can misinterpret phenomena like pseudoprogression, where an initial increase in tumor size precedes a durable response. The immune Response Evaluation Criteria in Solid Tumors (iRECIST) were developed to address this complexity. This exercise will test your ability to apply these nuanced rules to a clinical vignette, a critical skill for making correct decisions about continuing or discontinuing therapy in the face of ambiguous radiographic findings. ",
            "id": "4631794",
            "problem": "A $62$-year-old patient with metastatic melanoma underwent wide local excision and sentinel lymph node biopsy, followed by initiation of anti–Programmed Cell Death Protein $1$ (PD-$1$) therapy. Baseline contrast-enhanced computed tomography identified $4$ measurable target lesions with a summed longest diameter of $120$ $\\mathrm{mm}$. Non-target lesions were present but did not meet progression criteria. At the first on-treatment assessment at week $12$, the summed longest diameter of the original target lesions is $90$ $\\mathrm{mm}$, a new pulmonary nodule measuring $8$ $\\mathrm{mm}$ in longest diameter has appeared, and all non-target lesions remain clinically stable without new non-target progression. The patient is clinically stable without new or worsening symptoms.\n\nUsing the immune Response Evaluation Criteria in Solid Tumors (iRECIST), which option best classifies the response at this time point and indicates the appropriate immediate management?\n\nA. Immune unconfirmed progressive disease (iUPD) due to the new measurable lesion; continue therapy and repeat imaging in $4$–$8$ weeks to confirm progression versus response.\n\nB. Immune confirmed progressive disease (iCPD) because any new lesion represents confirmed progression; discontinue therapy.\n\nC. Immune partial response (iPR) because the sum of target lesions decreased by $25\\%$; continue therapy.\n\nD. Immune stable disease (iSD) because the decrease is less than $30\\%$ and non-target disease is stable; continue therapy and ignore the new lesion.\n\nE. Immune unconfirmed progressive disease (iUPD), but treat as response given target lesion shrinkage and forego confirmation imaging.",
            "solution": "The task requires application of the immune Response Evaluation Criteria in Solid Tumors (iRECIST) built upon the fundamental definitions from the Response Evaluation Criteria in Solid Tumors (RECIST) version $1.1$. The core principles needed are:\n\n- Under Response Evaluation Criteria in Solid Tumors (RECIST) version $1.1$, the overall response categorization integrates: target lesion response (based on changes in the sum of diameters), non-target lesion assessment (progression by unequivocal increase), and the appearance of new lesions (which, in classic RECIST, immediately indicates progressive disease).\n- Immune Response Evaluation Criteria in Solid Tumors (iRECIST) modifies RECIST to account for atypical immune response patterns (e.g., pseudoprogression). In iRECIST:\n  - Initial evidence of progression is designated immune unconfirmed progressive disease (iUPD).\n  - Confirmation of progression (immune confirmed progressive disease, iCPD) requires a subsequent assessment showing further progression compared to the iUPD timepoint (e.g., additional increase in the sum of target lesions of at least $20\\%$ from nadir with an absolute increase of at least $5$ $\\mathrm{mm}$, increase in size or number of new lesions totaling at least $5$ $\\mathrm{mm}$, or unequivocal progression of non-target lesions).\n  - New measurable lesions are recorded and summed separately; their initial appearance leads to iUPD, not immediate iCPD.\n  - If the patient is clinically stable at iUPD, continuation of therapy beyond progression with repeat imaging in approximately $4$–$8$ weeks is recommended to confirm progression or document response.\n\nStep $1$: Quantify the target lesion change. Baseline sum of target lesions $=$ $120$ $\\mathrm{mm}$; current sum $=$ $90$ $\\mathrm{mm}$. The proportional change is\n$$\n\\frac{120 - 90}{120} = \\frac{30}{120} = 0.25 = 25\\%.\n$$\nUnder RECIST version $1.1$, a partial response requires a decrease of at least $30\\%$ from baseline. Here, the decrease is $25\\%$, which does not meet the threshold for partial response. Absent any other progression signals, the target lesion component would be consistent with stable disease.\n\nStep $2$: Account for the new lesion. A new measurable lesion of $8$ $\\mathrm{mm}$ appears. Under classic RECIST version $1.1$, any new lesion results in progressive disease at that time point. Under iRECIST, the initial appearance of new lesions triggers immune unconfirmed progressive disease (iUPD), not confirmed progression. The new lesion should be measured, and the sum of new lesions should be tracked for confirmation criteria at the next scan.\n\nStep $3$: Integrate non-target lesions and clinical status. Non-target disease is stable without unequivocal progression, and the patient is clinically stable. iRECIST advises that clinically stable patients with iUPD may continue immunotherapy beyond progression pending confirmation on a subsequent assessment, typically in $4$–$8$ weeks.\n\nConclusion: The correct categorization at this timepoint is iUPD (due to the new lesion), with continuation of therapy and a plan for confirmation imaging to determine whether progression is confirmed (iCPD) or the patient reclassifies to immune stable disease (iSD) or immune partial response (iPR) if tumor burden decreases further or new lesion regresses.\n\nOption-by-option analysis:\n\n- Option A: Immune unconfirmed progressive disease (iUPD) due to the new measurable lesion; continue therapy and repeat imaging in $4$–$8$ weeks to confirm progression versus response. This precisely matches iRECIST rules: initial new lesion appearance leads to iUPD; if clinically stable, treatment may continue beyond progression with planned confirmation. Verdict — Correct.\n\n- Option B: Immune confirmed progressive disease (iCPD) because any new lesion represents confirmed progression; discontinue therapy. This statement reflects classic RECIST version $1.1$ logic but contradicts iRECIST, which requires confirmation of progression beyond iUPD. A single new lesion at first detection does not constitute iCPD. Verdict — Incorrect.\n\n- Option C: Immune partial response (iPR) because the sum of target lesions decreased by $25\\%$; continue therapy. iPR requires at least a $30\\%$ decrease from baseline. A $25\\%$ decrease does not meet iPR; furthermore, the new lesion precludes categorization as response at this timepoint under iRECIST and mandates iUPD. Verdict — Incorrect.\n\n- Option D: Immune stable disease (iSD) because the decrease is less than $30\\%$ and non-target disease is stable; continue therapy and ignore the new lesion. Ignoring the new lesion is incompatible with iRECIST; the new lesion causes iUPD, not iSD. Verdict — Incorrect.\n\n- Option E: Immune unconfirmed progressive disease (iUPD), but treat as response given target lesion shrinkage and forego confirmation imaging. Although iUPD is correct for categorization, management guidance is incorrect: iRECIST emphasizes confirmation on follow-up imaging to differentiate true progression from pseudoprogression. Foregoing confirmation is not appropriate. Verdict — Incorrect.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Modern surgical oncology extends far beyond the operating room, demanding the synthesis of complex data to formulate optimal perioperative treatment plans. This capstone problem simulates a multidisciplinary tumor board scenario, requiring you to integrate surgical pathology, disease staging, and a panel of molecular biomarkers including Microsatellite Instability–High (MSI-H) and $PIK3CA$ mutation status. Your task is to devise the most appropriate evidence-based adjuvant strategy, balancing standard-of-care chemotherapy with emerging immunotherapeutic concepts and targeted approaches. ",
            "id": "4631846",
            "problem": "A $62$-year-old man undergoes laparoscopic right hemicolectomy for colon adenocarcinoma. Final pathology shows a moderately differentiated adenocarcinoma invading through the muscularis propria into pericolonic fat, staged $pT3$ $pN1b$ with $3$ of $18$ lymph nodes positive and negative margins. Immunohistochemistry demonstrates loss of MutL Homolog $1$ (MLH$1$) and Postmeiotic Segregation Increased $2$ (PMS$2$), consistent with deficient Mismatch Repair (dMMR), and polymerase chain reaction confirms Microsatellite Instability–High (MSI-H). Next-generation sequencing identifies a Phosphatidylinositol-$4$, $5$-Bisphosphate $3$-Kinase Catalytic Subunit Alpha (PIK3CA) hotspot mutation ($E545K$), Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) and Neuroblastoma RAS Viral Oncogene Homolog (NRAS) wild-type, and v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) wild-type. Programmed Death-Ligand $1$ (PD-L1) immunohistochemistry shows a Combined Positive Score (CPS) of $15$. Preoperative computed tomography shows no distant metastases. He has excellent performance status and no major comorbidities or contraindications to chemotherapy or antiplatelet therapy.\n\nUsing the following foundational principles and facts:\n- Central Dogma of Molecular Biology (DNA $\\rightarrow$ RNA $\\rightarrow$ protein), where defective Mismatch Repair increases insertion–deletion errors at microsatellites, generating frameshift peptides and a high neoantigen burden.\n- The Programmed Death-$1$ (PD-$1$)/Programmed Death-Ligand $1$ (PD-L1) immune checkpoint attenuates T-cell effector function; blockade can restore antitumor immunity, with Microsatellite Instability–High (MSI-H)/deficient Mismatch Repair (dMMR) tumors showing enhanced sensitivity due to elevated neoantigens.\n- In resected colon cancer, adjuvant oxaliplatin-based chemotherapy such as Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for approximately $6$ months reduces recurrence and improves survival for pathologic Stage $III$ disease; single-agent $5$-fluorouracil shows limited benefit in dMMR tumors.\n- PD-L1 Combined Positive Score is not a validated predictive biomarker for colorectal cancer in the adjuvant setting.\n- PIK3CA mutations activate the phosphatidylinositol-$3$-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway; however, there are no approved adjuvant PI3K-targeted therapies for colon cancer. Observational data suggest that low-dose aspirin may confer survival benefit in PIK3CA-mutant colorectal cancer, though this is not a formal standard of care and requires individualized risk assessment.\n- Targeted monoclonal antibodies against Epidermal Growth Factor Receptor (EGFR), such as cetuximab, have no established role in the adjuvant treatment of colon cancer.\n\nWhich of the following is the most appropriate adjuvant plan?\n\nA. Initiate FOLFOX for approximately $6$ months; discuss enrollment in a dMMR/MSI-H adjuvant immunotherapy clinical trial using a PD-$1$ or PD-L1 inhibitor, without using PD-L1 CPS to select therapy; and consider low-dose aspirin (e.g., $81$ mg daily) given the PIK3CA mutation if no contraindications and after individualized risk–benefit discussion.\n\nB. Begin pembrolizumab monotherapy as adjuvant treatment based on MSI-H and PD-L1 CPS $15$ and omit chemotherapy to avoid immunosuppression.\n\nC. Add cetuximab to FOLFOX because the tumor is RAS/BRAF wild-type and PD-L1 CPS is $15$, enhancing targeted activity in the adjuvant setting.\n\nD. Use alpelisib (PI3K-$\\alpha$ inhibitor) combined with endocrine therapy to target the PIK3CA mutation and omit chemotherapy, as PI3K-targeted therapy has proven adjuvant benefit in resected colon cancer.\n\nE. Choose single-agent $5$-fluorouracil adjuvant therapy because MSI-H/dMMR tumors are resistant to oxaliplatin and will not benefit from combination chemotherapy.",
            "solution": "### Step 1: Extract Givens\n\nThe verbatim data, definitions, conditions, and principles provided in the problem statement are as follows:\n\n**Patient and Disease Characteristics:**\n- A $62$-year-old man.\n- Procedure: Laparoscopic right hemicolectomy for colon adenocarcinoma.\n- Final pathology: Moderately differentiated adenocarcinoma invading through the muscularis propria into pericolonic fat.\n- Stage: $pT3$ $pN1b$ with $3$ of $18$ lymph nodes positive and negative margins.\n- Immunohistochemistry (IHC): Loss of MutL Homolog $1$ (MLH$1$) and Postmeiotic Segregation Increased $2$ (PMS$2$), consistent with deficient Mismatch Repair (dMMR).\n- Polymerase chain reaction (PCR): Confirms Microsatellite Instability–High (MSI-H).\n- Next-generation sequencing (NGS): Phosphatidylinositol-$4,5$-Bisphosphate $3$-Kinase Catalytic Subunit Alpha (PIK3CA) hotspot mutation ($E545K$), Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) and Neuroblastoma RAS Viral Oncogene Homolog (NRAS) wild-type, and v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) wild-type.\n- Programmed Death-Ligand $1$ (PD-L1) IHC: Combined Positive Score (CPS) of $15$.\n- Staging Imaging: Preoperative computed tomography shows no distant metastases.\n- Patient Fitness: Excellent performance status and no major comorbidities or contraindications to chemotherapy or antiplatelet therapy.\n\n**Foundational Principles and Facts:**\n- **Central Dogma and Mismatch Repair:** Defective Mismatch Repair increases insertion–deletion errors at microsatellites, generating frameshift peptides and a high neoantigen burden (DNA $\\rightarrow$ RNA $\\rightarrow$ protein).\n- **Immune Checkpoint Blockade:** The Programmed Death-$1$ (PD-$1$)/Programmed Death-Ligand $1$ (PD-L1) immune checkpoint attenuates T-cell effector function. Blockade can restore antitumor immunity, with Microsatellite Instability–High (MSI-H)/deficient Mismatch Repair (dMMR) tumors showing enhanced sensitivity due to elevated neoantigens.\n- **Adjuvant Chemotherapy Standard:** In resected colon cancer, adjuvant oxaliplatin-based chemotherapy such as Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for approximately $6$ months reduces recurrence and improves survival for pathologic Stage $III$ disease. Single-agent $5$-fluorouracil shows limited benefit in dMMR tumors.\n- **PD-L1 Biomarker Status:** PD-L1 Combined Positive Score is not a validated predictive biomarker for colorectal cancer in the adjuvant setting.\n- **PIK3CA Pathway:** PIK3CA mutations activate the phosphatidylinositol-$3$-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. There are no approved adjuvant PI3K-targeted therapies for colon cancer. Observational data suggest that low-dose aspirin may confer survival benefit in PIK3CA-mutant colorectal cancer, though this is not a formal standard of care and requires individualized risk assessment.\n- **EGFR Targeted Therapy:** Targeted monoclonal antibodies against Epidermal Growth Factor Receptor (EGFR), such as cetuximab, have no established role in the adjuvant treatment of colon cancer.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is a clinical vignette that is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding:** The case is biomedically and clinically sound. The patient's pathology ($pT3N1b$), molecular markers (dMMR/MSI-H, $PIK3CA$, $KRAS$/$BRAF$ wild-type), and the provided foundational principles accurately reflect established knowledge in oncology, molecular biology, and immunology.\n- **Well-Posedness:** The problem is structured to have a single \"most appropriate\" answer derivable by applying the provided principles to the patient's data. It is self-contained and provides all necessary information to evaluate the therapeutic options.\n- **Objectivity:** The problem is presented using precise, unbiased clinical and scientific language, free of subjective claims.\n\nThe problem does not violate any of the specified invalidity criteria. It is a valid, complex, and realistic problem in clinical decision-making.\n\n### Step 3: Verdict and Action\n\nThe problem is valid. The solution process will now proceed by analyzing the case in light of the provided principles and evaluating each option.\n\n### Derivation of the Correct Adjuvant Plan\n\nThe goal is to determine the most appropriate adjuvant plan for a $62$-year-old man with resected Stage $IIIB$ ($pT3$ $pN1b$) dMMR/MSI-H colon cancer. The patient's tumor is also $KRAS$/$NRAS$/$BRAF$ wild-type and has a $PIK3CA$ mutation.\n\n1.  **Standard Chemotherapy:** The patient has Stage $III$ colon cancer. The provided principles state, \"adjuvant oxaliplatin-based chemotherapy such as... (FOLFOX) for approximately $6$ months reduces recurrence and improves survival for pathologic Stage $III$ disease.\" This establishes FOLFOX as the standard of care. The principles also note that \"single-agent $5$-fluorouracil shows limited benefit in dMMR tumors,\" which argues against using $5$-FU monotherapy. Therefore, an oxaliplatin-based combination regimen is the appropriate chemotherapy backbone.\n\n2.  **Immunotherapy Consideration:** The tumor is MSI-H/dMMR, which, according to the principles, confers \"enhanced sensitivity\" to PD-$1$/PD-L1 blockade. While immunotherapy is a cornerstone of treatment for *metastatic* MSI-H colorectal cancer, its role in the *adjuvant* setting is an area of active investigation. A prudent and evidence-based approach is to offer the standard-of-care chemotherapy while considering enrollment in clinical trials exploring adjuvant immunotherapy for this highly responsive subgroup. The principles also state that \"PD-L1 Combined Positive Score is not a validated predictive biomarker for colorectal cancer in the adjuvant setting.\" Therefore, the patient's CPS of $15$ should not influence the decision to use or select an immunotherapy agent in this context; the MSI-H status is the guiding biomarker.\n\n3.  **Targeted Therapy Considerations:**\n    - **EGFR pathway:** The tumor is $RAS$/$BRAF$ wild-type. However, a specific principle states that \"EGFR... antibodies... have no established role in the adjuvant treatment of colon cancer.\" Thus, adding cetuximab is inappropriate.\n    - **PI3K pathway:** The tumor has a $PIK3CA$ mutation. The principles are clear that \"there are no approved adjuvant PI3K-targeted therapies for colon cancer.\" This rules out PI3K inhibitors like alpelisib. However, the principles mention that \"observational data suggest that low-dose aspirin may confer survival benefit in PIK3CA-mutant colorectal cancer, though this is not a formal standard of care and requires individualized risk assessment.\" Given that the patient has no contraindications to antiplatelet therapy, discussing the risks and potential benefits of low-dose aspirin is a reasonable, personalized consideration.\n\n**Synthesized Plan:** The most appropriate plan integrates these points: initiate the standard-of-care adjuvant FOLFOX, discuss enrollment in a clinical trial for adjuvant immunotherapy based on MSI-H status (not PD-L1 score), and consider low-dose aspirin based on the $PIK3CA$ mutation after a careful risk-benefit analysis.\n\n### Option-by-Option Analysis\n\n**A. Initiate FOLFOX for approximately $6$ months; discuss enrollment in a dMMR/MSI-H adjuvant immunotherapy clinical trial using a PD-$1$ or PD-L1 inhibitor, without using PD-L1 CPS to select therapy; and consider low-dose aspirin (e.g., $81$ mg daily) given the PIK3CA mutation if no contraindications and after individualized risk–benefit discussion.**\nThis option aligns perfectly with the derived plan. It correctly identifies FOLFOX as the standard chemotherapy for Stage $III$ disease. It appropriately frames adjuvant immunotherapy as an investigational approach to be pursued within a clinical trial, correctly citing MSI-H as the biomarker and dismissing the PD-L1 score. Finally, it correctly describes the nuanced, non-standard consideration of low-dose aspirin for the $PIK3CA$-mutant tumor.\n**Verdict: Correct**\n\n**B. Begin pembrolizumab monotherapy as adjuvant treatment based on MSI-H and PD-L1 CPS $15$ and omit chemotherapy to avoid immunosuppression.**\nThis option is incorrect for two primary reasons based on the provided principles. First, it presents an investigational strategy (adjuvant immunotherapy as a single agent) as the definitive standard, bypassing the established standard of care (FOLFOX for Stage $III$ disease). Second, it uses the PD-L1 CPS of $15$ as part of the justification, which directly contradicts the principle that PD-L1 CPS is not a validated predictive biomarker in this setting.\n**Verdict: Incorrect**\n\n**C. Add cetuximab to FOLFOX because the tumor is RAS/BRAF wild-type and PD-L1 CPS is $15$, enhancing targeted activity in the adjuvant setting.**\nThis option is fundamentally flawed. It violates the explicit principle that \"Targeted monoclonal antibodies against... (EGFR), such as cetuximab, have no established role in the adjuvant treatment of colon cancer.\" The $RAS$/$BRAF$ wild-type status, while relevant for metastatic disease, does not justify its use in the adjuvant setting.\n**Verdict: Incorrect**\n\n**D. Use alpelisib (PI3K-$\\alpha$ inhibitor) combined with endocrine therapy to target the PIK3CA mutation and omit chemotherapy, as PI3K-targeted therapy has proven adjuvant benefit in resected colon cancer.**\nThis option contains multiple falsehoods according to the provided principles. It claims \"proven adjuvant benefit\" for PI3K-targeted therapy, directly contradicting the principle that \"there are no approved adjuvant PI3K-targeted therapies for colon cancer.\" Furthermore, endocrine therapy has no role in the management of colon cancer.\n**Verdict: Incorrect**\n\n**E. Choose single-agent $5$-fluorouracil adjuvant therapy because MSI-H/dMMR tumors are resistant to oxaliplatin and will not benefit from combination chemotherapy.**\nThis option is incorrect. It recommends single-agent $5$-fluorouracil, a therapy the principles explicitly state has \"limited benefit in dMMR tumors.\" It also makes the unsubstantiated claim that dMMR tumors are \"resistant to oxaliplatin\" and derive no benefit from combination chemotherapy, which is an oversimplification and is inconsistent with the primary recommendation of FOLFOX for Stage $III$ disease.\n**Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}